SPECIALTY AREAS
 

Biochemistry

 

Bioinformatics

Biology

Biomedical Science

Biopharmaceutical Manufacturing

Biophysics

Cancer Biology

Drug Delivery

Genetics

Immunology

Medical Devices

Microbiology

Molecular Biology

Molecular Genetics

Nanotechnology

Pharmaceuticals

Pharmacology

Physiology

Stem Cell Biology

Virology

Jeff X. Zhou, Ph.D.

Patent Agent

Dr. Jeff X. Zhou, a registered U.S. patent agent at Johnson, Marcou, Isaacs & Nix (JMIN), specializes in patent drafting and prosecuting oncology, immunology and molecular biology inventions. He is fluent in English and Chinese and has drafted patent applications for U.S. and Chinese biotech companies. He has worked closely with scientists to identify innovations and develop intellectual property strategies, conduct prior art research, devise strategies for amendments, and to overcome rejections. 

 

Prior to joining JMIN, Zhou was a consultant for Rockville Biology Laboratory LLC in Rockville, Md. Before his consultancy position, he was a faculty member at Ningbo University School of Medicine in Ningbo, China and a director at KingMed Diagnostics in Guangzhou, China. He has held many research and scientific positions at prestigious organizations and companies, including the National Institute of Allergy and Infectious Disease, the National Cancer Institute, and Large Scale Biology Corp. in Maryland, as well as Johnson & Johnson in New Jersey. Some of his biomedical experience includes leading translational research teams for cancer biomarker discovery and clinical validation. He has written 38 peer-reviewed research papers that have been published in influential scientific journals. 

 

Zhou earned his doctorate in Biochemistry at The University of British Columbia in Vancouver, Canada. He received a Bachelor of Medicine in Clinical Medicine at Southern Medical University in Guangzhou, China. 

 

Publications

Leukemia & Lymphoma 

  • Jiang L, Fang R, Ouyang G, Zhou JX(2018) The tumor suppressive role of INHBA in diffuse large B-cell lymphoma. Leukemia & Lymphoma. 59:1202-1212.

  • Si T, Lu Y, Jiang L, Li F, Pei R, Zhou JX(2018) High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. Leukemia & Lymphoma. 59:114-120.

  • Pei R, Si T, Lu Y, Zhou JX, Jiang L (2018) Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia. Leukemia & Lymphoma. 59:1959-1967.

  • Qi C-F, Xiang S, Ouyang G, Hao X, Shin M, Kovalchuk AL, Liang P, Xiong X, Morse HC III, Zhuang Z, Zhou JX, Pierce SK (2016) TMEM4 is Highly Expressed in Plasma Cell Neoplasms and Associated with B Lymphocyte Differentiation. Immunological Disorders and Immunotherapy. 1:102. 

  • Jiang L, Xu Y, Zeng X, Fang J, Morse HC 3rd, Zhou JX(2015) Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma. Oncotarget. 6:31191-31202. 

  • Xu Y, Jiang L, Fang J, Fang R, Morse HC 3rd, Ouyang G, Zhou JX(2015) Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma. Journal of Cancer. 6:953-961. 

  • Zhou JX, Lee CH, Qi CF, Huang HS, Abais, S, Morse HC 3rd(2009) IFN regulatory factor 8 regulates MDM2 in germinal center B cells. Journal of Immunology. 183:3188-3194. 

  • Qi CF, Zhou JX, Lee CH, Naghashfar Z, Xiang S, Kovalchuk AL, Fredrickson TN, Hartley JW, Roopenian DC, Davidson WF Janz S, Morse HC 3rd(2007) Anaplastic, Plasmablastic, and Plasmacytic Plasmacytomas of Mice: Relationships to Human Plasma Cell Neoplasms and Late stage Differentiation of Normal B Cells. Cancer Research 67:2439-2447.

  • Lee CH, Melchers M, Wang H, Torrey TA, Slota R, Qi CF, Kim JY, Lugar P, Kong HJ, Farrington L, van der Zouwen B, Zhou JX, Lougaris V, Lipsky PE, Grammer AC, Morse HC 3rd(2006) Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. Journal of Experimental Medicine 203:63-72. 

  • Hao X, Shin MS, Zhou JX, Lee CH, Qi CF, Naghashfar Z, Hartley JW, Fredrickson TN, Ward JM, Morse HC 3rd(2006) Histologic and molecular characterizations of megakaryocytic leukemia in mice. Leukemia Research 30:397-406. 

  • Qi CF, Xiang S, Shin, MS, Hao X, Lee CH, Zhou JX, Torrey TA, Hartley JW, Fredrickson TN, Morse HC 3rd (2005) Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas, Leukemia Research 30:153-163. 

  • Zhang, JQ, Okumura C, McCarty T, Torrey TA, Shin MS, Lee CH, Hori M, Naghashfar Z, Zhou JX, Rooperian DC, Morse HC 3rdand Davidson WF (2004) Evidence for selective transformation of autoreactive immature plasma cells in mice deficient in Fas1. Journal of Experimental Medicine200:1467-78.

 

Lung Cancer

  • Yang P, Li WL, Zhou JX, Yang YB, Jin XX (2017) Peritoneum as the sole distant metastatic site of lung adenosquamous cell carcinoma: a case report. Journal of Medical Case Reports.11(1):274. 

  • Zhou JX, Yang X, Ning S, Wang L, Wang K, Zhang Y, Yuan F, Li F, Zhuo DD, Tang L, Zhuo D (2017) Identification of KANSARL as the first cancer predisposition fusion gene specific to the population of European ancestry origin. Oncotarget. 8:50594-50607.

  • Huang Q, Deng Q, Jiang L, Fang R, Qiu Y, Wang P, Zhou JX*, Yang H* (2016) Assessment of ALKgene fusions in lung cancer using the differential expression and exon integrity methods. Oncology Letters. 11:1651-1656.  (* senior author)

  • Deng Q, Yang H, Lin Y, Qiu Y, Gu X, He P, Zhao M, Wang H, Xu Y, Lin Y, Jiang J, He J, Zhou JX(2014) Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China. International Journal of Clinical Experimental Pathology7:8312-8321. 

  • Zhou JX, Yang H, Deng Q, Gu X, He P, Lin Y, Zhao M, Jiang J, Chen H, Lin Y, Yin W, Mo L, He J (2013) Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. Annals of Oncology24:1319-1325. 

  • Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW(2012) Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer.77:9-15.

  • Bloom GC, Eschrich S, Zhou JX, Coppola D, Yeatman TJ (2007) Elucidation of a protein signature discriminating six common types of adenocarcinoma. International Journal of Cancer 120:769-775.

 

Colorectal, Pancreatic, and Other Types of Cancer

  • Zhuang H, Meng X, Li Y, Wang X, Huang S, Liu K, Hehir M, Fang R, Jiang L, Zhou JX, Wang P, Ren Y (2016) Cyclic AMP responsive element-binding protein promotes renal cell carcinoma proliferation probably via the expression of spindle and kinetochore-associated protein 2. Oncotarget. 7:16325-16337. 

  • Dai L, Lu C, Yu X, Dai LJ, Zhou JX(2015) Construction of orthotopic xenograft mouse models for human pancreatic cancer. Experimental & Therapeutic Medicine. 10:1033-1038. 

  • Huang S, Ren Y, WangP, Li Y, WangX, Zhuang H, Fang R, WangY, Liu N, Hehir M, ZhouJX(2015) Transcription factor CREB is involved in CaSR-mediated cytoskeleton gene expression.Anatomy Record(Hoboken). 298:501-512. 

  • Liao W, Liao Y, Zhou JX, Xie J, Chen J, Huang W, Luo R (2010) Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. Anatomy Record(Hoboken) 293:1506-1511.

  • Bloomston M, Zhou JX*, Rosemurgy AS, Frankel W, Muro-Cacho CA, Yeatman TJ (2006) Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Research 66:2592-2599. (*, co-first author)

  • Kwong KY, Bloom GC, Yang I, Boulware D, Coppola D, Haseman J, Chen E, McGrath A, Makusky AJ, Taylor J, Steiner S, Zhou JX, Yeatman TJ, Quackenbush J. (2005) Synchronous global assessment of gene and protein expression in colorectal cancer progression. Genomics86:142-58. 

  • Li G, Tang L, Zhou X, Tron VA, and Ho V (1998) Chemotherapy-induced apoptosis in melanoma cells is p53-dependent. Melanoma Research 8:17-23. 

  • Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G, Zhou X, Ho VC, Trotter MJ (1998) Expression of apoptosis regulators in cutaneous malignant melanoma. Clinical Cancer Research 4:1865-1871.

 

Other Cancer-Related Research

  • Dai LJ*, Moniri MR, Zeng ZR, Zhou JX*, Rayat J, Warnock GL (2011) Potential implications of mesenchymal stem cells in cancer therapy. Cancer Letter305:8-20. (*, senior author)

  • Dai LJ, Li HY, Guan LX, Ritchie G, Zhou JX (2009) The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Research 2:16-25. 

  • Merrick BA, Bruno ME, Madenspacher JH, Wetmore BA, Foley J, Pieper R, Zhao M, Makusky AJ, McGrath AM, Zhou JX, Taylor J, Tomer KB (2006) Alterations in the Rat Serum Proteome During Liver Injury from Acetaminophen Exposure. Journal of Pharmacology and Experimental Therapeutics 318:792-802. 

  • Kim H, Zhou, JX, Park H and Morse HC 3rd(2005) A three-stage framework for gene expression data analysis by L1-norm support vector regression. International Journal of Bioinformatics Research & Application 1:51-62. 

  • Hildesheim J, Belova GI, Tyner SD, Zhou X, Vardanian L, and Fornace Jr, AJ (2004) Gadd45a regulates matrix metalloproteinases by suppressing Np63 and beta-catenin via p38 MAP kinase and APC complex activation. Oncogene 23:1829-1837. 

  • Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, Su Q, McGrath AM, Estock MA, Parmar PP, Zhao M, Huang ST,Zhou JX, Wang F, Esquer-Blasco R, Anderson NL, Taylor J, Steiner S (2003) The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 3:1345-1364. 

  • Gosiewska A, Rezania A, Dhanaraj S, Vyakarnam M, Zhou J, Burtis D, Brown L, Kong W, Zimmerman M, Geesin JC (2001) Development of a three-dimensional transmigration assay for testing cell—polymer interactions for tissue engineering applications. Tissue Engineering 7:267-277.

  • Zhou X, Tron VA, Li G, and Trotter MJ (1998) Heat shock transcription factor-1 regulates heat shock protein-72 expression in human keratinocytes exposed ultraviolet B light.Journal of Investigative Dermatology 111:194-198. 

  • Zhou Xand Thompson JR (1997) Regulation of protein turnover by glutamine in heatshocked skeletal myotubes. Biochimica et Biophysica Acta 1357:234-242. 

  • Zhou Xand Thompson JR (1996) Regulation of glutamate dehydrogenase by branchedchain amino acids in skeletal muscle from rats and chicks. The International Journal of Biochemistry and Cell Biology 28:787-793. 

  • Zhou Xand Thompson JR (1995) Glutamine increases heat shock protein 72 expression in skeletal muscle cells at transcriptional level. Journal of Celularl Biochemistry Suppl.19B:207.

 

Education

  • Ph.D., Biochemistry, The University of British Columbia, Vancouver, Canada

  • Bachelor of Medicine, Clinical Medicine, Southern Medical University, Guangzhou, China

 

Admitted to Practice

  • United States Patent and Trademark Office Registered Patent Agent

  • Regulatory Affairs Certificate (RAC), RAPS

Email:   jzhou@jmin-iplaw.com

Direct:  240.766.8995

Please reload

PRIVACY & TERMS

Johnson, Marcou, Isaacs & Nix, LLC ("JMIN") will collect names and email addresses from its visitors to be used solely to respond to questions regarding the services we offer and/or general intellectual property questions.  All personal data received (names and email addresses) shall be considered confidential and will never be sold to third parties.

© 2020 Johnson, Marcou, Isaacs & Nix, LLC

  • LinkedIn Social Icon